Horizon Pharma’s Actimmune has missed the primary endpoint in a phase 3 trial, sparking a 20% drop in its stock price.

In this week's EuroBiotech Report, uniQure’s ASH fizzles, EMA accepts Sanofi drug for review, TiGenix tees up IPO and more.

Armed with debut financing of $44.5 million, Cambridge-based startup TCR2 Therapeutics is poised to advance its cell-based cancer therapies toward the clinic.

South Korean biotech Eutilex has seen a $21 billion KRW ($18.9 million) Series A funding boost as it looks to take its lead cancer med into midstage testing.

Shares in Voyager Therapeutics jumped 35% in after-hours trading on the back of interim data from an early trial of its Parkinson’s disease gene therapy.

Allaying concerns from some quarters that it wouldn’t be passed this year, and coming just one month after the presidential election, the 21st Century Cures…

Nordic Nanovector has raised $60 million to test its CD37-targeting antibody-radionuclide conjugate in combination with rituximab.

AbbVie missed its survival targets in a new midstage trial of its PARP breast cancer candidate veliparib in combo with chemo, but the company is still hopeful…